Advertisement

Effect of a Proton Pump Inhibitor Deprescribing Guideline on Drug Usage and Costs in Long-Term Care

      Abstract

      Objectives

      To assess the effect of a proton pump inhibitor (PPI) deprescribing guideline on PPI usage and PPI drug costs in one long-term care home in Ontario, Canada.

      Design

      Interrupted time-series analysis to compare monthly PPI usage and average monthly PPI cost per resident 9 months before guideline implementation to 12 months after.

      Setting

      One long-term care home in Ottawa, Ontario, Canada.

      Participants

      Long-term care residents prescribed a PPI over a 21-month period (n = 335).

      Intervention

      PPI deprescribing guideline and decision support tool used during quarterly medication reviews.

      Measurements

      (1) Total number of PPI prescriptions (PPI usage) and (2) average PPI drug cost per resident. We also measured the proportion of residents whose PPI was deprescribed in the preguideline period and postguideline period.

      Results

      The deprescribing guideline was associated with a decrease in PPI usage but the association was not statistically significant (−8.7 prescriptions, 95% confidence interval [CI] −22.0 to 4.6). The PPI guideline led to a significant decrease in average monthly PPI drug cost per resident over time (0.16 CAD reduction per month; 95% CI −0.29 to −0.03). In the 9 months before intervention, 57 (27.8%) of 205 eligible residents had their PPI deprescribed, and in the 12 months after intervention 134 (50.0%) of 268 eligible residents had their PPI deprescribed (difference in proportions of 22.2%; 95% CI 13.4–30.4).

      Discussion/conclusion

      The deprescribing guideline was associated with a decline PPI usage; however, this negative association was not statistically significant. PPI usage declined in the initial 6 months after guideline implementation but began to climb back to baseline after this, which may explain the lack of a significant reduction in PPI usage. This suggests that it was difficult to maintain PPI deprescribing efforts long-term. Although implementation of a PPI deprescribing guideline may lead to an initial reduction in PPI usage, and a significant reduction in the average cost of PPI prescriptions over time, it is imperative to explore ways to sustain deprescribing guideline use.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the American Medical Directors Association
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Katz P.O.
        • Gerson L.B.
        • Vela M.F.
        Guidelines for the diagnosis and management of gastroesophageal reflux disease.
        Am J Gastroenterol. 2013; 108: 308-328
        • Reeve E.
        • Andrews J.M.
        • Wiese M.D.
        • et al.
        Feasibility of a patient-centered deprescribing process to reduce inappropriate use of proton pump inhibitors.
        Ann Pharmacother. 2015; 49: 29-38
        • Leri F.
        • Ayzenberg M.
        • Voyce S.J.
        • et al.
        Four-year trends of inappropriate proton pump inhibitor use after hospital discharge.
        South Med J. 2013; 106: 270-273
        • Heidelbaugh J.J.
        • Kim A.H.
        • Chang R.
        • Walker P.C.
        Overutilization of proton-pump inhibitors: What the clinician needs to know.
        Therap Adv Gastroenterol. 2012; 5: 219-232
        • Ladd A.M.
        • Panagopoulos G.
        • Cohen J.
        • et al.
        Potential costs of inappropriate use of proton pump inhibitors.
        Am J Med Sci. 2014; 347: 446-451
        • Glew C.M.
        • Rentler R.J.
        Use of proton pump inhibitors and other acid suppressive medications in newly admitted nursing facility patients.
        J Am Med Dir Assoc. 2007; 8: 607-609
        • Masclee G.M.
        • Sturkenboom M.C.
        • Kuipers E.J.
        A benefit-risk assessment of the use of proton pump inhibitors in the elderly.
        Drugs Aging. 2014; 31: 263-282
        • Kwok C.S.
        • Arthur A.K.
        • Anibueze C.I.
        • et al.
        Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: Meta-analysis.
        Am J Gastroenterol. 2012; 107: 1011-1019
        • Eom C.
        • Jeon C.
        • Lim J.
        • et al.
        Use of acid-suppressive drugs and risk of pneumonia: A systematic review and meta-analysis.
        CMAJ. 2011; 183: 310-319
        • Yu E.
        • Bauer S.
        • Bain P.
        • Bauer D.
        Proton pump inhibitors and risk of fractures: A meta-analysis of 11 international studies.
        Am J Med. 2012; 124: 519-526
      1. Canadian Institute for Health Information. Prescribed drug spending in Canada, 2012: A focus on public drug programs spending and health workforce. 2014. Available at: https://secure.cihi.ca/free_products/Prescribed_Drug_Spending_in_Canada_EN.pdf. Accessed March 11, 2016.

        • Farrell B.
        • Pottie K.
        • Thompson W.
        • et al.
        Evidence-based deprescribing algorithm for proton pump inhibitors.
        (Available at:) (Accessed March 11, 2016)
        • Conklin J.
        • Farrell B.
        • Ward N.
        • et al.
        Developmental evaluation as a strategy to enhance the uptake and use of deprescribing guidelines: Protocol for a multiple case study.
        Implement Sci. 2015; 10: 91
      2. Ontario Drug Benefit Formulary. Formulary search 2016. Available at: https://www.healthinfo.moh.gov.on.ca/formulary/. Accessed March 11, 2016.

        • Kontopantelis E.
        • Doran T.
        • Springate D.A.
        • et al.
        Regression based quasi-experimental approach when randomisation is not an option: Interrupted time series analysis.
        BMJ. 2015; 350: h2750
        • Prior M.
        • Guerin M.
        • Grimmer-Somers K.
        The effectiveness of clinical guideline implementation strategies—a synthesis of systematic review findings.
        J Eval Clin Pract. 2008; 14: 888-897
        • Haastrup P.
        • Paulsen M.S.
        • Begtrup L.M.
        • et al.
        Strategies for discontinuation of proton pump inhibitors: A systematic review.
        Fam Pract. 2014; 31: 625-630
        • Krol N.
        • Wensing M.
        • Haaijer-Ruskamp F.
        • et al.
        Patient-directed strategy to reduce prescribing for patients with dyspepsia in general practice: A randomized trial.
        Aliment Pharmacol Ther. 2004; 19: 917-922
        • Linsky A.
        • Hermos J.A.
        • Lawler E.V.
        • Rudolph J.L.
        Proton pump inhibitor discontinuation in long-term care.
        J Am Geriatr Soc. 2011; 59: 1658-1664
        • Bundeff A.W.
        • Zaiken K.
        Impact of clinical pharmacists’ recommendations on a proton pump inhibitor taper protocol in an ambulatory care practice.
        J Manag Care Pharm. 2013; 19: 325-333
        • Wagner A.K.
        • Soumerai S.B.
        • Zhang F.
        • Ross-Degnan D.
        Segmented regression analysis of interrupted time series studies in medication use research.
        J Clin Pharm Ther. 2002; 27: 299-309